third clinical trial approval outside of china received — eu application for clinical trial of henlius bevacizumab hlx04-o approved for ophthalmologic indication
in october 2020, henlius entered into a co-development and exclusive license agreement with essex. with this collaboration, henlius and essex plan to conduct global multi-centre clinical trials of hlx04 in china, australia, the european union and the united states, and apply marketing authorization in different countries and regions around the globe based on the research results. previously, a series of studies including non-clinical pharmacodynamics, safety pharmacology, repeat-dose toxicity, pharmacokinetics, toxicokinetics, immunotoxicity, immunogenicity and local irritation of hlx04-o vitreous injection in the treatment of wamd have been carried out, initially proving the efficacy and safety of hlx04-o. the phase 3, global and multi-centre clinical study of hlx04-o is intended to commence in china, australia, russian federation, singapore, spain and poland in the near future to further evaluate the efficacy and safety of hlx04-o for the treatment of wamd.
it is believed that henlius and essex will speed up the global multicentre clinical trials of hlx04-o and apply marketing authorization in different countries and regions around the globe based on the research results. hlx04-o has the potential to be one of the first bevacizumabs approved for ophthalmic diseases, benefiting more patients with eye diseases worldwide. looking forward, henlius will continue advancing the development of innovative biologics on the basis of its established and integrated innovation platform, underscoring its long-term commitment to providing affordable and effective therapies for patients worldwide.
age-related macular degeneration is one of the leading causes of visual impairment and blindness in the elderly worldwide. according to the world health organization (who), about 30 million people have suffered from amd globally, and about half a million people become blind due to amd each year. wet age-related macular degeneration (wamd) is characterized by the formation of subretinal choroidal neovascularization (cnv) and is responsible for approximately 90% of cases of amd-related blindness. due to an aging population, wamd has become a serious social medical problem and indicated a huge burden of unmet need. with the development of treatment for fundus diseases, anti-vegf drugs are becoming the first-line therapy for the management of wamd, and the efficacy and safety of vitreous injection of bevacizumab for wamd have been verified in multiple clinical studies-6.
hlx04-o is a new ophthalmic preparation product developed based on hlx04, a bevacizumab biosimilar independently developed by the company, through optimizing the prescription, specifications and production processes of hlx04 according to the requirements of ophthalmic drugs, without changing the active ingredients, and is intended to be used for the treatment of wamd. by means of comparability studies, it shows that changes in production processes and prescriptions of the preparation have no adverse impact on the quality, safety and efficacy of the pharmaceutical preparation. hlx04-o can inhibit vegf’s binding to its receptor flt-1(vegfr-1) and kdr(vegfr-2) on endothelial cells to inhibit the activation of its tyrosine kinase signaling pathway, inhibit endothelial cell proliferation and reduce angiogenesis, thereby treating eye diseases associated with angiogenesis. in january and march 2021, hlx04-o for the treatment of wamd has been approved to commence clinical trials in australia and the united states.
henlius (2696.hk) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. up to date, 3 products have been launched in china, 1 in the european union (eu), the new drug applications (nda) of 2 products accepted for review in china. since its inception in 2010, henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including r&d, manufacturing and commercialisation. it has established global r&d centers and a shanghai-based manufacturing facility certificated by china and the eu good manufacturing practice (gmp).
henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies (mabs) and has continued to explore immuno-oncology combination therapies with proprietary hlx10 (anti-pd-1 mab) as backbone. apart from the launched products 汉利康® (rituximab), the first china-developed biosimilar, 汉曲优® (trastuzumab, zercepac® in the eu), the first china-developed mab biosimilar approved both in china and in the eu and 汉达远® (adalimumab), the company's first product indicated for autoimmune diseases, the nda of hlx04 (bevacizumab) and hlx01 (rituximab) for the treatment of rheumatoid arthritis are under review. what's more, henlius has conducted over 20 clinical studies for 10 products and 8 combination therapies worldwide, expanding its presence in major market as well as emerging market.
 欧阳灵艺, 邢怡桥. 抗vegf药物在湿性年龄相关性黄斑变性中的应用进展[j]. 国际眼科杂志, 2020(1).
 resnikoff s, pascolini d, etya'ale d, kocur i, pararajasegaram r, pokharel gp, mariotti sp. global data on visual impairment in the year 2002. bull world health organ. 2004 nov;82(11):844-51.
 wong wl, su x, li x, et al. global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. lancet glob health. 2014;2(2):e106-116.
 li x r , liu j p . recognition of anti-vegf therapy base on the mechanism of vegf in wet age-related macular degeneration[j]. zhonghua shiyan yanke zazhi/chinese journal of experimental ophthalmology, 2012, 30(4):289-292.
 tufail a, patel pj, egan c, hykin p, da cruz l, gregor z, dowler j, majid ma, bailey c, mohamed q, johnston r, bunce c, xing w; abc trial investigators. bevacizumab for neovascular age related macular degeneration (abc trial): multicentre randomized double masked study. bmj. 2010 jun 9;340:c2459.
 martin df, maguire mg, ying gs, grunwald je, fine sl, jaffe gj. ranibizumab and bevacizumab for neovascular age-related macular degeneration. n engl j med. 2011 may 19;364(20):1897-908.
 chakravarthy u, harding sp, rogers ca, downes sm, lotery aj, wordsworth s, reeves bc. ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the ivan randomized trial. ophthalmology. 2012 jul;119(7):1399-411.
 kodjikian l, souied eh, mimoun g, mauget-faÿsse m, behar -cohen f, decullier e, huot l, aulagner g; gefal study group. ranibizumab versus bevacizumab for neovascular agerelated macular degeneration: results from the gefal noninferiority randomized trial. ophthalmology. 2013 nov;120(11):2300-9.
 krebs i, schmetterer l, boltz a, told r, vécsei-marlovits v, egger s, schönherr u, haas a, ansari-shahrezaei s, binder s; manta research group. a randomized double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. br j ophthalmol. 2013 mar;97(3):266-71.
 berg k, pedersen tr, sandvik l, bragadóttir r. comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to lucas treat-and-extend protocol. ophthalmology. 2015 jan;122(1):146-52.
 schauwvlieghe am, dijkman g, hooymans jm, verbraak fd, hoyng cb, dijkgraaf mg,peto t, vingerling jr, schlingemann ro. comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration. the bramd study. plos one. 2016 may 20;11(5):e0153052.